Prof Swapna Chaudhuri, M.Sc., Ph.D. - Emeritus Medical Scientist, Chittaranjan - Professor

Prof Swapna Chaudhuri

M.Sc., Ph.D.

Emeritus Medical Scientist, Chittaranjan

Professor

Kolkata , West Bengal | India

Main Specialties: Allergy & Immunology, Clinical & Laboratory Immunology, Neuropathology, Oncology

Additional Specialties: Immunology and Immunotherapy

ORCID logohttps://orcid.org/0000-0002-8924-8066


Top Author

Prof Swapna Chaudhuri, M.Sc., Ph.D. - Emeritus Medical Scientist, Chittaranjan - Professor

Prof Swapna Chaudhuri

M.Sc., Ph.D.

Introduction

Prof Swapna Chaudhuri is an alumnus of University of Calcutta.Presently has joined Chittaranjan National Cancer Institute as Emeritus Medical Medical scientist , ICMR. She has superannuated from School of Tropical Medicine, where she was the Professor & Head of Dept. of Laboratory Medicine.. Her research area is in the fields of Cancer Immunology and Immunotherapy, Respiratory and Infectious Immunology and Immunotherapy and Haematopoietic Stem cell Immunology and Immunotherapy. Taught at both postgraduate and undergraduate levels. Published seventy five papers in peer reviewed journals and also has published reviews, monograms, book chapters.Has one patent. Has won many Academic laurels and Fellowships, affiliated to twelve Academic Societies, Editorial Committee member of many National and International journals, Reviewer of 56 high impact factor journals, Principal Investigator of twenty one projects, Supervised 21 PhD, MD and DM students and co-guided 5 PhD students.

Primary Affiliation: Emeritus Medical Scientist, Chittaranjan - Kolkata , West Bengal , India

Specialties:

Additional Specialties:

Research Interests:


View Prof Swapna Chaudhuri’s Resume / CV

Education

Jun 1986
Calcutta University
M.Sc
Jun 1984
Calcutta University
Ph.D.

Publications

53Publications

695Reads

401Profile Views

22PubMed Central Citations

Unravelling the apoptotic mechanisms in T-lymphocytes in an animal model for pollen induced airway allergy and studying the impact of specific immunotherapy.

Immunobiology 2019 03 16;224(2):183-195. Epub 2018 Nov 16.

Department of Laboratory Medicine, School of Tropical Medicine, 108 C. R. Avenue, Kolkata, 700073, West Bengal, India. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.imbio.2018.11.008DOI Listing
March 2019
18 Reads
3.044 Impact Factor

T11TS immunotherapy augments microglial and lymphocyte protective immune responses against Cryptococcus neoformans in the brain.

Scand J Immunol 2019 Feb 27;89(2):e12733. Epub 2018 Dec 27.

Department of Laboratory Medicine, School of Tropical Medicine, Kolkata, India.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/sji.12733DOI Listing
February 2019
36 Reads
1.882 Impact Factor

T11TS Treatment Augments Apoptosis of Glioma Associated Brain Endothelial Cells, Hint Toward Anti-Angiogenic Action in Glioma.

J Cell Physiol 2017 Mar 21;232(3):526-539. Epub 2016 Jun 21.

Cellular and Molecular Immunology Laboratory, Department of Laboratory Medicine, School of Tropical Medicine, Kolkata, India.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/jcp.25447DOI Listing
March 2017
20 Reads
3.840 Impact Factor

Modulation of regulatory T cells by intranasal allergen immunotherapy in an experimental rat model of airway allergy

Int Immunopharmacol. 47 ,9–19

Int Immunopharmacol.

Allergic airway diseases such as asthma and allergic rhinitis are increasing in prevalence worldwide. The theory of an altered Th1/Th2 balance in allergic diathesis has recently been termed a “procrustean paradigm” as it failed to explain many preclinical findings. Regulatory T cells (Treg) have now been shown to be critical in T-cell homeostasis and in the maintenance of peripheral tolerance to allergens. Allergen specific immunotherapy (SIT) has been shown to induce regulatory T cells in allergic patients. Among various types of SIT, intranasal immunotherapy had not been studied in detail for the treatment of allergic airway diseases. So, there was a need to study the contribution of regulatory T cells and their mechanistic pathways following intranasal immunotherapy invivo. It had been previously shown that intranasal allergen immunotherapy using Alstonia scholaris pollen extract abrogates allergic airway inflammation with decline in IgE and Th2 cytokine levels. The present study for the first time offers a multi-targeted approach towards attenuation of airway allergy by the generation of CD4 + CD25 +Foxp3+T cells and other subsets of Treg cells like Tr1 cells, Th3 cells, CTLA4+Treg cells, and also modulation of various Treg cell surface molecules like GITR, OX40, CD39 and CD73 by intranasal immunotherapy in the same animal model. This animal experiment will thus help to chart out newer molecular targets for treating allergic asthma or rhinitis.

View Article
March 2017
10 Reads

T11TS repress gliomagenic apoptosis of bone marrow hematopoietic stem cells.

J Cell Physiol. 2017;9999:1–22

J Cell Physiol.

Combating gliomagenic global immunosuppression is one of the emerging key for improving prognosis in malignant glioma. Apoptosis plays a pivotal role within the adult hematopoietic system particularly in regulating the cells of immune system. Gliomagenic regulation of apoptotic mediators within bone marrow milieu has not been elucidated. We previously demonstrated that administration of membrane glycopeptides T11 target structure (T11TS) not only rejuvenate bone marrow hematopoietic stem cells (BMHSCs) from glioma mediated hibernation by inhibiting gliomagenic overexpression of Ang-1/Tie-2 but also stimulate glioma mediated diminution of expression CD34, c-kit, and Sca-1 markers. In the present study, we investigated the impact of glioma on apoptotic signaling cascades of BMHSCs and consequences following T11TS therapy. Bone marrow smear and Annexin V staining confirm gliomagenic acceleration of apoptotic fate of BMHSCs whereas T11TS treatment in gliomabearing rats disrupted apoptosis of BMHSCs. Flowcytometry, immunoblotting, and immunofluorescence imagining results revealed multi potent T11TS not only significantly downregulates gliomagenic overexpression of Fas, Fas L, Bid, and caspase-8, the pro-apoptotic extrinsic mediators but also strongly inhibits cytosolic release of cytochrome-c, Apf-1, and Bax to deactivate gliomagenic caspase-9, 3 the key intrinsic apoptotic mediators followed by up modulation of anti-apoptotic Bcl-2 in glioma associated HSCs. T11TS is also able to diminish the perforin-granzyme B mediated apoptotic verdict of BMHSCs during gliomagenesis. The antiapoptotic action of T11TS on glioma associated BMHSCs provide a crucial insight into how T11TS exerts its immunomodulatory action against glioma mediated immune devastation.

View Article
February 2017
11 Reads

Signals derived from the commensal microbiota to promote intestinal tumor development

Translational Cancer Research; 5(3). doi: 10.21037/tcr.2016.09.39

Translational Cancer Research

View Article
August 2016
8 Reads

Signals derived from the commensal microbiota to promote intestinal tumor development.

Translational Cancer Research; 5(3). doi: 10.21037/tcr.2016.09.39

Translational Cancer Research

View Article
August 2016
8 Reads

Microglial Contribution to Glioma Progression: an Immunohistochemical Study in Eastern India

Asian Pacific Journal of Cancer Prevention, Vol 17, 2016 2767 APJCP.2016.17.6.2767 Microglial Contri

Asian Pac J Cancer Prev

Human glioma, arising from glial cells of the central nervous system, accounts for almost 30%of all brain tumours , neoplasms with a poor prognosis and high mortality rates worldwide. In the present study we assessed tissue architectural modifications associated with macrophage lineage cells, controversial major immune effector cells within the brain, in human glioma tissue samples from eastern India. Ethically cleared post-operative human glioma samples from our collaborative neurosurgery unit with respective CT/MRI and patient history were collected from the Nodal Centre of Neurosciences in Kolkata, over 9 months. Along with conventional histopathology, samples were subjected to silver-gold staining and fluorescence tagged immunophenotyping for the detection of electron dense brain macrophage/microglia cells in glioma tissue, followed by immune-phenotyping of cells. With higher grades, CD11b+/Iba-1+ macrophage/microglia architecture with de-structured boundaries of glioma lesions indicated malfunction and invasive effector state. Present study documented a contribution of microglia to glioma progression in Eastern India.

View Article
June 2016
10 Reads

A mathematical model to elucidate brain tumor abrogation by immunotherapy with T11 target structure.

PLoS One 2015 8;10(5):e0123611. Epub 2015 May 8.

Department of Laboratory Medicine, School of Tropical Medicine, Kolkata-700073, West Bengal, India.

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0123611PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4425651PMC
February 2016
18 Reads
2 Citations
3.234 Impact Factor

Specific allergen immunotherapy attenuates allergic airway inflammation in a rat model of Alstonia scholaris pollen induced airway allergy.

Int Immunopharmacol 2016 Jan 5;30:111-120. Epub 2015 Dec 5.

Department of Laboratory Medicine, School of Tropical Medicine, 108 C. R. Avenue, Kolkata 700073, West Bengal, India. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.intimp.2015.12.004DOI Listing
January 2016
29 Reads
2.472 Impact Factor

Disease relevance of T11TS-induced T-cell signal transduction through the CD2-mediated calcineurin-NFAT pathway: Perspectives in glioma immunotherapy.

Mol Immunol 2015 Oct 21;67(2 Pt B):256-64. Epub 2015 Jun 21.

Cellular and Molecular Immunology Laboratory, Department of Laboratory Medicine, School of Tropical Medicine, 108, C. R. Avenue, Kolkata, 700073 West Bengal, India. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.molimm.2015.06.002DOI Listing
October 2015
79 Reads
2 Citations
2.973 Impact Factor

T11TS inhibits Angiopoietin-1/Tie-2 signaling, EGFR activation and Raf/MEK/ERK pathway in brain endothelial cells restraining angiogenesis in glioma model.

Exp Mol Pathol 2015 Jun 19;98(3):455-66. Epub 2015 Mar 19.

Cellular and Molecular Immunology Laboratory, Department of Laboratory Medicine, School of Tropical Medicine, 108 C. R. Avenue, Kolkata 700073, West Bengal, India. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.yexmp.2015.03.026DOI Listing
June 2015
13 Reads
1 Citation
2.710 Impact Factor

T11 target structure induced modulations of the pro-inflammatory and anti-infammatorycytokine expressions in experimental animals for glioma abrogation.

Int Immunopharmacol 2015 Feb 17;24(2):198-207. Epub 2014 Dec 17.

Department of Laboratory Medicine, School of Tropical Medicine, 108, C.R. Avenue, Kolkata 700073, West Bengal, India. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.intimp.2014.12.010DOI Listing
February 2015
16 Reads
2.472 Impact Factor

The novel immunotherapeutic molecule T11TS modulates glioma-induced changes of key components of the immunological synapse in favor of T cell activation and glioma abrogation.

J Neurooncol 2014 Oct 16;120(1):19-31. Epub 2014 Jul 16.

Department of Laboratory Medicine, School of Tropical Medicine, Cellular and Molecular Immunology Lab, 108, C. R. Avenue, Kolkata, 700073, West Bengal, India.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11060-014-1528-9DOI Listing
October 2014
61 Reads
3.070 Impact Factor

T11TS inhibits glioma angiogenesis by modulation of MMPs, TIMPs, with related integrin αv and TGF-β1 expressions.

Tumour Biol 2014 Mar 19;35(3):2231-46. Epub 2013 Nov 19.

Department of Laboratory Medicine, School of Tropical Medicine, 108, C.R. Avenue, Kolkata, 700073, West Bengal, India.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s13277-013-1296-8DOI Listing
March 2014
23 Reads
4 Citations
2.840 Impact Factor

Significant modulation of macrophages associated cytokines TNF-α, VEGF and apoptotoic protein Bax, Bcl2 abrogates tumor cells.

Cell Immunol 2013 Jul-Aug;284(1-2):172-81. Epub 2013 Aug 8.

Department of Laboratory Medicine, School of Tropical Medicine, 108 Chittaranjan Avenue, Kolkata 700 073, India. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cellimm.2013.07.020DOI Listing
March 2014
22 Reads
1 Citation
1.924 Impact Factor

T11TS impedes glioma angiogenesis by inhibiting VEGF signaling and pro-survival PI3K/Akt/eNOS pathway with concomitant upregulation of PTEN in brain endothelial cells.

J Neurooncol 2013 May 8;113(1):13-25. Epub 2013 Mar 8.

Immunology Research Laboratory, Department of Laboratory Medicine, School of Tropical Medicine, 108 C. R. Avenue, Kolkata 700073, India.

View Article

Download full-text PDF

Source
http://search.proquest.com/openview/1e7fce7b472bf4bd3b38dafa
Web Search
http://link.springer.com/10.1007/s11060-013-1095-5
Publisher Site
http://dx.doi.org/10.1007/s11060-013-1095-5DOI Listing
May 2013
29 Reads
3 Citations
3.070 Impact Factor

Therapeutic profile of T11TS vs. T11TS+MiADMSA: a hunt for a more effective therapeutic regimen for arsenic exposure.

Asian Pac J Cancer Prev 2012 ;13(6):2943-8

Department of Laboratory Medicine, School of Tropical Medicine, Kolkata, India.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7314/apjcp.2012.13.6.2943DOI Listing
February 2013
30 Reads
1.500 Impact Factor

Immunomodulatory role of TIITS in respect to cytotoxic lymphocytes in four grades of human glioma.

Cell Immunol 2012 Mar-Apr;276(1-2):176-86. Epub 2012 May 23.

Department of Laboratory Medicine, School of Tropical Medicine, 108 Chittaranjan Avenue, Kolkata 700073, India.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cellimm.2012.05.006DOI Listing
October 2012
39 Reads
1.924 Impact Factor

Comparative evaluation of T11 target structure and its deglycosylated derivative nullifies the importance of glycan moieties in immunotherapeutic efficacy.

Acta Biochim Biophys Sin (Shanghai) 2012 Mar 18;44(3):259-68. Epub 2012 Jan 18.

Department of Laboratory Medicine, Calcutta School of Tropical Medicine, Kolkata, West Bengal, India.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/abbs/gmr120DOI Listing
March 2012
10 Reads
2.191 Impact Factor

Comparative Evaluation of T11TS and Its Deglycosylated Derivative Nullifies the Importance of Glycan Moieties in Immunotherapeutic Efficacy

Acta Biochim Biophys Sin 2012, 44: 259–268

Acta Biochim et Biophys Sinica

Sheep red blood cell (SRBC), a non-specific biological response modifier that has long been used as a classical antigen, has been shown to exert an immunomodulatory and anti-tumor activities in experimental animals. The active component of SRBC, which is responsible for such effects, was found to be a cell surface acidic glycoprotein molecule, known as T11 target structure (T11TS). In the present study, T11TS was isolated and purified to homogeneity using a five-step protocol involving isolation of sheep erythrocyte membrane from packed cell volume, 20% ammonium sulfate cut of the crude membrane proteins mixture, immunoaffinity purification using mouse anti-sheep CD58 mAb (L180/1) tagged matrix, preparative gel electrophoresis, and gel electroelution process. Finally, the purity and identity of the proteins were confirmed by the matrix-assisted laser desorption/ionization (MALDI) mass spectrometric analysis. The in silico glycosylation site analysis showed that the extracellular domain contained three N-glycosylation sites (N-12, N-62, and N- 111) and one O-glycosylation site (T-107). However, the experimental analysis negated the presence of O-linked glycan moieties on T11TS. To investigate the role of glycan moieties in the current immunotherapeutic regime, T11TS and its deglycosylated form (dT11TS) were administered intraperitoneally (i.p.) in N-ethyl-N-nitrosoureainduced immune-compromised mice at 0.4 mg/kg body weight. It was observed that both the forms of T11TS could activate the compromised immune status of mice by augmenting immune receptor expression (CD2, CD25, CD8, and CD11b), T-helper 1 shift of cytokine network, enhanced cytotoxicity, and phagocytosis activity. Therefore, the results nullify the active involvement of the N-linked glycan moieties in immunotherapeutic efficacy of T11TS.

View Article
October 2011
9 Reads

Insilico structural analysis of an immunotherapeutic glycoprotein T11TS.

Int J Biol Med Res. 2011; 2(1): 346-359

Int J Biol Med Res

T11-Target Structure (T11TS) is a 42 K SRBC membrane glycoprotein and the classical ligand of the E-receptor (CD2). It is an important costimulator of T cell activation process. Therapeutic potential of the bioactive molecule has recently been deciphered and thus necessitated structural analysis. 3D structure of extracellular domain (residues 2-192) of T11TS was generated using 1CCZ_A as template by web based molecular modeling program 'LOOPP' and refined by energy minimization (SD and CG) and molecular dynamics simulations in cff91.frc force field. Structural quality assessment of the final model with six high throughput structure validation programs (PROCHECK, MODELYN, MOLPROBITY, VERIFY_3D, ERRAT and PROSA) demonstrated its reliability for further studies. Secondary structural analysis reveals that 41.36%, 21.99%, 3.66%, 3.14% and 29.84% residues of the final model form â-sheet, bend, turn, 310 helix and coil conformations respectively. Insilico analysis of the three receptorligand complexes viz. T11TS-humanCD2, T11TS-ratCD2 and T11TS-mouseCD2 highlight that the main interacting residues (Met27, Phe29, Lys32, Asp33, Lys34, Glu37, Asp39, Gln40 and Phe47) are highly conserved and located in a heterophilic, charged AGFCC'C? face on the Nterminal IgV domain of T11TS. Intermolecular hydrogen bonding and electrostatic force play a prominent role in these receptor-ligand interactions. Although the CD2 binding domain contains two potential N-type glycosylation sites (N-12, and N-62) but none is found to be present within 4A0 of the CD2 binding interface, implies their probable functional silence in immune activation process. The phylogenetic analysis using KITSH program shows that T11TS and bovine CD58 are closely related to each other.

View Article
June 2011
12 Reads

Immunological profile of arsenic toxicity: a hint towards arsenic-induced carcinogenesis.

Asian Pac J Cancer Prev 2010 ;11(2):479-90

Department of Laboratory Medicine, School of Tropical Medicine, Kolkata, India.

View Article

Download full-text PDF

Source
March 2011
21 Reads
1 Citation
1.500 Impact Factor

T11 target structure exerts effector function by activating immune cells in CNS against glioma where cytokine modulation provide favorable microenvironment.

Indian J Exp Biol 2010 Sep;48(9):879-88

Department of Laboratory Medicine, School of Tropical Medicine, 108, CR Avenue, Kolkata 700 073, India.

View Article

Download full-text PDF

Source
September 2010
14 Reads
0.840 Impact Factor

Microglial action in glioma: A boon turns bane.

Immunology Letters 131 (2010) 3–9

Immunology Letters

Microglia has the potential to shape the neuroimmune defense with vast array of functional attributes. The cells prime infiltrated lymphocytes to retain their effector functions, play crucial role in controlling microenvironmental milieu and significantly participate in glioma. Reports demonstrate microglial accumulation in glioma and predict their assistance in glioma growth and spreading. Clarification of the ‘double-edged’ appearance of microglia is necessary to unfold its role in glioma biology. In this article the interpretation of microglial activities has been attempted to reveal their actual function in glioma. Contrary to the trendy acceptance of its glioma promoting infamy accumulated evidences make an effort to view the state of affairs in favor of the cell. Critical scrutiny indicates that microglial immune assaults are intended to demolish the neoplastic cells in brain. But the weaponry of microglia has been tactically utilized by glioma in their favor as the survival strategy. Hence the defender appears as enemy in advanced glioma.

View Article
March 2010
9 Reads

Induction of G1 arrest in glioma cells by T11TS is associated with upregulation of Cip1/Kip1 and concurrent downregulation of cyclin D (1 and 3).

Anticancer Drugs 2010 Jan;21(1):53-64

Department of Laboratory Medicine, School of Tropical Medicine, Kolkata, West Bengal, India.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CAD.0b013e32833276e8DOI Listing
January 2010
14 Reads
1.891 Impact Factor

A comparative analysis of immunorestoration and recovery with conventional and immunotherapeutic protocols in canine generalized demodicosis: a newer insight of immunotherapeutic efficacy of T11TS

Immunol Invest,2009, 33(4): 457-472

Immunological Investigations

Demodex canis is a natural inhabiting mite of canine skin. Immunological disorder or genetic disorder induces the Demodex population to proliferate vigorously resulting in generalized demodicosis with consequent chronic immunosuppression. Signs of generalized demodicosis include alopecia, crysting, erythema, secondary pyoderma etc. Amitraz, an acaricide, is used conventionally for the treatment of generalized demodicosis. In many instances, the disease relapses due to the residual immunosuppression. The need of an immunorestorative therapy has been urged in generalized demodicosis. Two immunorestorative drugs, namely, Immuplus, a herbal drug, and T11TS, a sheep erythrocyte surface glycoprotein, has been used in two separate groups of dogs having generalized demodicosis and receiving Amitraz treatment. It was observed that though Amitraz treated group responded to the therapy showing increased E‐rosettes and nonspecific cytotoxic efficacy of T‐lymphocytes and decrease in phagocytic potential of macrophages, the groups treated with the immunotherapeutics like Immuplus and T11TS, responded better. However, the group treated with T11TS showed best recovery. These results emphasize the need for an immunorestorative therapy in generalized demodicosis and provide data in favor of T11TS as a better immunomodulator in comparison to Immuplus.

View Article
August 2009
9 Reads

Bax and Bid act in synergy to bring about T11TS mediated glioma apoptosis via the release of mitochondrial Cytochrome c and subsequent caspase activation.

International Immunology, Vol. 20, No. 12, pp. 1489–1505

Int Immunol

The specific apoptotic role of T11TS has been well established in glioma animal models. T11TS specifically induces the glioma cells to die an apoptotic death via immune cross-talk with the two intracranial immune competent cells—microglia and the brain-infiltrating lymphocytes. To unearth the molecular cascades operative within the glioma cells and to some extent in the two interacting immunocytes, we had initiated studies where preliminary findings not only had indicated the involvement of death receptors but had also hinted to the involvement of other apoptotic regulators. Hence, to identify the molecular pathway of apoptosis involving other apoptotic regulators in the three cell types, the cells were studied for the intrinsic apoptotic death regulators that were engaged to maintain the mitochondrial membrane integrity. The proteins that were selected could be divided into three broad classes—the Bcl-2 family of proteins—Bid, Bax and Bcl-2; the guardian of the genome p53 and the proteins downstream of mitochondria-Apaf-1, cytochrome c, caspase-9 and caspase-3. Activated Bid as well as maximal p53 expression was observed in the first dose of T11TS thus dually activating the pro-apoptotic Bax in the first and second dose in the glioma cells. Concurrently, the pro-survival protein Bcl-2’s expression level was very much down-regulated in the same two doses favoring the internal microenvironment to proceed for apoptosis. High expression of cytochrome c and Apaf-1 and the presence of active caspase-9 and active caspase-3 in all the T11TStreated tumor-bearing groups further adjudicated apoptosis of the glioma cells with clear involvement of mitochondrial death pathway in the T11TS-treated animals. Even though expression of the apoptotic regulators remained more or less the same indicating the involvement of mitochondria in the two interacting immunocytes, the intensity of expression of these proteins was much lower than the tumor cells. The present work focuses on the mechanistic approach of how T11TS mediates apoptosis and hence is the first approach of its kind in the field of immunology where the immunotherapeutic molecule’s mode of action has been worked out.

View Article
April 2008
8 Reads

T11TS/SLFA-3 Differentially Regulate the population of Microglia and Brain Infiltrating Lymphocytes to reduce Glioma by modulating Intrinsic Bcl-2 Expression Rather than p53.

CNS Agents in Med Chem, 2007,7:145-155.

CNS Agents in Med Chem

T11TS/SLFA-3, the glycoprotein isolated from sheep erythrocyte membrane, acts as an antineoplastic agent causing apoptotic elimination of glioma cells through cell mediated immune response. Therefore, elucidation of the proper balance in proliferation and apoptosis of neuroimmune components viz. microglia and brain infiltrating lymphocytes with the neoplastic glial cells was the fundamental issue to establish the efficacy of T11TS as a therapeutic agent in glioma. To decipher its effectivity on proliferation rate of glioma cells, expression of GFAP and cell cycle phase distribution was analyzed with propidium iodide (PI) staining. The apoptotic regulation of interacting immuno-competent microglia, lymphocytes entering into the brain and target glioma cells were elucidated by cytoplasmic DNA fragmentation assay and phosphatidylserine (PS) externalization along with intrinsic p53 and Bcl-2 modulation of the cells. With the reduction of cellular proliferation rate, sharp increase of apoptosis in consecutive doses of T11TS showed the regression of glioma, where an increase of cytosolic p53 and a decrease of Bcl-2 with doses in these neoplastic cells facilitate the process. Resident microglia, the chief immunomodulator of brain, was found to show a low and steady level of proliferation and apoptosis, furnishing it as a stable pool of cell capable of controlling immune reaction in brain compartment. However, microglia showed higher basal level of p53 than other cells and modulated with T11TS dose, it was found to possess a steady level of Bcl-2 that aided to maintain low rate of apoptosis. Brain infiltrating lymphocytes showed increased apoptosis in tumorigenic condition and initial treatment phase mostly due to immuno-suppressive milieu and deprivation of microglial restimulation. But the second dose of T11TS showed reduced apoptosis, enhanced activation of lymphocytes and final dose acting as a regulatory dose, which reduce the infiltrating lymphocytes by apoptotic elimination. Wide fluctuation of cytosolic p53 was observed in these lymphocytes, but anti-apoptotic Bcl-2 was found to modulate apoptosis in the cells. Thus, T11TS was found to differentially regulate the population of immune effector cells against glioma to exert effective effector function in eradication of neoplastic cells where Bcl-2 constitutively suppresses pro-apoptotic function of p53. Regulation of the directionality of these balances of cellular life and death in favor of glioma killing and also maintaining homeostasis in brain tissue after reaction established T11TS as an effective therapeutic probe against glioma

View Article
June 2007
7 Reads

The Other Side of the Coin: Beneficiary Effect of ‘Oxidative Burst’ Upsurge with T11TS Facilitates the Elimination of Glioma Cells

Cellular and Molecular Biology, France.2007, 53(5), 53-62

Cellular and Molecular Biology, France

Free radicals and allied molecules are the potential threats for the cellular components when they are produced in excess amount and cause different pathophysiological disorders including aging. Contrary to their detrimental effects, these molecules, in the other hand, can be utilized by the Phagocytic cells to destroy the abnormal cells and cellular components. Generation of reactive oxygen species (ROS) and nitric oxide (NO) are used as important effector molecules by Phagocytic macrophage/microglia to eliminate neoplastic cells in glioma bearing rat model. The glycoprotein T11TS/SLFA-3, by binding with CD2 receptor of macrophage/microglia, induces the generation of these reactive species when applied in three consecutive doses in glioma bearing animals. The CR3 family receptor CD11b is also correlated with the Phagocytic activity of the cells. The ‘controlled’ and directed production of ROS and NO by phagocytes induce cell death signals to the glioma cells and resulted in phagocytic destruction and apoptosis. The death signals generated by the free radicals and associated molecules resulted in accumulation of p53 proteins in the glioma cells. This oxidative stress induced p53 protein accumulation in neoplastic cells direct them to die by apoptosis. Therefore, the same oxidative stress causing pathophysiological problems, are used here to destroy the glioma cells by the macrophage/microglia in the delicate CNS tissue.

View Article
May 2007
10 Reads

Glioma Therapy: A Novel Insight in the Immunotherapeutic Regime with T11TS/SLFA-3

Central Nervous System Agents in Medicinal Chemistry, 2006, 6(4): 245-27

Central Nervous System Agents in Medicinal Chemistry

Brain tumors of glial origin i.e. glioma are most difficult neoplasm to treat with modern therapeutic interventions viz. surgery, radio- and chemotherapies. Therefore, a continuous search is on for the alternative modalities of treatment particularly with different immunomolecular therapeutic regimes. Use of restorative and adaptive immunotherapies with different BRMs, cytokines, tumor vaccines, site directed therapies with molecular blocking agents are now practiced to combat with glioma and still no major breakthrough has been obtained to extend life expectancy significantly. In our laboratory a novel immunotherapeutic probe i.e. T11TS/SLFA3, a membrane glycoprotein of sheep erythrocyte, with its activities of glioma killing in experimental animals has been attempted. With the fundamental details of neuroimmune components, particularly the resident microglia and brain infiltrating lymphocytes, the modulation of their activities by T11TS was evidenced. The activation of microglia, infiltration of lymphocytes, enhanced performance of effector functions and regulation of the cytokine network with T11TS in the brain compartment superseding the glioma induced immune suppression, is the major achievement found with T11TS mediated immunotherapy. These immune effector functions are culminated into the clearance of glioma, which is clearly depicted by the study of apoptosis and cell cycle analysis. This molecule with the carnage of glioma differentially regulates the population of microglia and lymphocytes in brain to regain homeostasis by modulating intrinsic cellular protein levels. Additionally, when this glycoprotein is used for toxicological evaluation, it showed mearly no adverse effects on animals, rather health promotion. Therefore, this glycoprotein T11TS potentially provides an effective immunotherapeutic option against glioma with the potentials of new drug development.

View Article
June 2006
9 Reads

ENU administration causes genomic instability along with single nucleotide polymorphisms in p53 during gliomagenesis: T11TS administration demonstrated in vivo apoptosis of these genetically altered tumor cells.

Cancer Biol Ther 2006 Feb 10;5(2):156-64. Epub 2006 Feb 10.

Cellular & Molecular Immunology Lab, Department of Physiology, Dr. B.C. Roy Post Graduate Institute of Basic Medical Sciences, Institute of Post Graduate Medical Education And Research (I.P.G.M.&R.), Kolkata, West Bengal, India.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4161/cbt.5.2.2313DOI Listing
February 2006
7 Reads
3 Citations
3.072 Impact Factor

A comparative analysis of immunorestoration and recovery with conventional and immunotherapeutic protocols in canine generalized demodicosis: a newer insight of immunotherapeutic efficacy of T11TS.

Immunol Invest 2004 ;33(4):453-68

Cellular and Molecular Immunology Laboratory, Department of Physiology, Dr. B.C. Roy Post Graduate Institute of Basic Medical Sciences, Institute of Post Graduate Medical Education and Research, 244B, A.J.C. Bose Road, Kolkata 700020, India.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1081/imm-200038753DOI Listing
November 2005
5 Reads
1 Citation
1.903 Impact Factor

Immunotherapy with T11TS / S-LFA-3 specifically induces apoptosis of brain tumor cells by augmenting intracranial immune status.

Anticancer Res 2005 Jul-Aug;25(4):2905-19

Cellular and Molecular Immunology Laboratory, Department of Physiology, Dr. B. C. Roy Postgraduate Institute of Basic Medical Sciences, 244 B, A. J. C. Bose Road, Kolkata - 700 020, West Bengal, India.

View Article

Download full-text PDF

Source
September 2005
24 Reads
1.872 Impact Factor

Sheep erythrocyte demonstrated better effect than IL-2 and IFN-gamma as biological response modifier against glioma in experimental model.

Indian J Exp Biol 2005 May;43(5):414-9

Cellular & Molecular Immunology Lab, Department of Physiology, Dr BC Roy Institute of Basic Medical Sciences, Institute of Post Graduate Medical Education and Research, Kolkata 700 020, India.

View Article

Download full-text PDF

Source
May 2005
16 Reads
0.840 Impact Factor

T11TS/S-LFA3 induces apoptosis of the brain tumor cells: a new approach to characterise the apoptosis associated genetic changes by arbitrarily primed-PCR.

Cancer Lett 2005 May;222(1):23-38

Cellular and Molecular Immunology Lab, Department of Physiology, Dr B. C. Roy Post Graduate Institute of Basic Medical Sciences, Institute of Post Graduate Medical Education and Research, Kolkata, West Bengal, India.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.canlet.2004.09.014DOI Listing
May 2005
14 Reads
5.621 Impact Factor

CD2-SLFA3/T11TS interaction facilitates immune activation and glioma regression by apoptosis.

Cancer Biol Ther 2004 Nov 9;3(11):1121-8. Epub 2004 Nov 9.

Cellular and Molecular Immunology Lab, Department of Physiology, Dr. B.C. Roy Institute of Basic Medical Sciences, Institute of Post Graduate Medical Education and Research (IPGME&R) Kolkata 700020, India.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4161/cbt.3.11.1214DOI Listing
November 2004
42 Reads
2 Citations
3.072 Impact Factor

The first cross sectional survey on intracranial malignancy in Kolkata, India: reflection of the state of the art in southern West Bengal.

Asian Pac J Cancer Prev 2004 Jul-Sep;5(3):259-67

Cellular & Molecular Immunology Lab, Department of Physiology, IPGME&R, Kolkata, Westbengal, India.

View Article

Download full-text PDF

Source
October 2004
27 Reads
1.500 Impact Factor

Differential regulation of the protein tyrosine kinase activity following interleukin-2 (IL-2), interferron gamma (IFN-gamma) and SRBC administration in brain tumor-induced conditions: SRBC acting as a dual potentiator in regulating the cytokine profile.

Cancer Biol Ther 2004 Aug 12;3(8):755-60. Epub 2004 Aug 12.

Cellular and Molecular Immunology Lab, Department of Physiology, Dr. B.C. Roy Postgraduate Institute of Basic Medical Sciences, Institute of Postgraduate Medical Education and Research, Kolkata, India.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4161/cbt.3.8.969DOI Listing
August 2004
9 Reads
3.072 Impact Factor

Evaluation of anti-tumor property of specific and non-specific BRMs in experimental gioma by assessing the microglial cell functional and phenotypic modulations.

Cancer Biol Ther 2003 Jul-Aug;2(4):356-63

Cellular and Molecular Immunology Lab, Department of Physiology, University College of Medicine; Kolkata, India.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4161/cbt.2.4.423DOI Listing
June 2004
13 Reads
3.072 Impact Factor

Begum Z, Ghosh A, Sarkar S, Mukherjee J, Mazumdar M, Sarkar P and Chaudhuri Swapna (2004). Documentation of immune profile of microglia through cell surface marker study in glioma model primed by a novel cell surface glycopeptide T11TS/SLFA-3

Glycoconjugate Journal 20, 515–523, 2004

Glycoconj J

The sheep erythrocyte membrane glycoprotein T11TS/SLFA-3 can form a ligand-receptor complex with CD2 present on immunocyte and exert stimuli for activation and proliferation. Regression of brain tumor with the application of T11TS indicates the probable role of microglia, the chief immunomodulatory cell within the brain compartment. In the present study microglial activation and immunophenotypic modulation were assessed in T11TS treated brain tumor-bearing animal models. Rat glioma models induced by chemical carcinogen ENU were treated with three consecutive doses of T11TS. Microglial cells from brain were isolated and assessed through E-rosette formation, SEM and FACS for CD2, MHC class II, CD25, and CD4. The preliminary indication of presence of CD2 on microglia through E-rosette formation was confirmed by SEM and FACS. MHC class II and CD2 single and double positive subpopulations exist, and their expression is also modulated in different doses of T11TS. A general trend of highest receptor saturation and microglial activation, measured through the activation marker CD25 and CD4 expression, was observed in 2nd dose of T11TS administration, which was then dampened via a complex immune feedback mechanism in the 3rd dose.

View Article
June 2004
8 Reads

Immunotherapeutic effects of T11TS/S-LFA3 against nitrosocompound mediated neural genotoxicity.

Toxicol Lett 2004 May;150(3):239-57

Department of Physiology, Cellular and Molecular Immunology Lab, Dr. B.C. Roy Post Graduate Institute of Basic Medical Sciences, Institute of Post Graduate Medical Education and Research, 244 B, J.C. Bose Road, Kolkata 700020, West Bengal, India.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.toxlet.2004.01.016DOI Listing
May 2004
14 Reads
1 Citation
3.262 Impact Factor

Brain tumor inhibition in experimental model by restorative immunotherapy with a corpuscular antigen.

Indian J Exp Biol 2003 Aug;41(8):805-13

Immunology Section, Department of Pathology, University College of Medicine, 244B, A.J.C. Bose Road, Kolkata 700020, India.

View Article

Download full-text PDF

Source
August 2003
12 Reads
0.840 Impact Factor

Sheep form of leucocyte function antigen-3 (T11TS) exerts immunostimulatory and anti-tumor activity against experimental brain tumor. A new approach to biological response modifier therapy.

J Exp Clin Cancer Res 2002 Mar;21(1):95-106

Dept. of Physiology, University College of Medicine, Kolkata, India.

View Article

Download full-text PDF

Source
March 2002
8 Reads

Preclinical Changes in Immunoreactivity and Cellular Architecture during the Progressive Development of Intracranial Neoplasms and an Immunotherapeutic Schedule with a Novel Biological Response Modifier, the T11TS / S-LFA3.

Asian Pac J Cancer Prev 2002 ;3(4):325-337

Department of Physiology, University College of Medicine, Dr. B. C. Roy Postgraduate Institute of Basic Medical Sciences, Kolkata - 700 020. West Bengal, India.

View Article

Download full-text PDF

Source
January 2002
12 Reads
1 Citation
1.500 Impact Factor

Law S, Maiti D, Palit A, Majumdar D, Basu K, Chaudhuri Swapna and Chaudhuri S

Immunol Lett,2001, 76:145 152

Immunol Lett

Biological Response Modifiers (BRMs) including interleukin-2 (IL-2), interferon-gamma (IFN-γ) and sheep erythrocytes (SRBC) protected N,N′-ethylnitrosourea (ENU) induced leukaemic mice. Two cell types from the bone marrow were isolated in density specific gradient representing two distinct compartments, the low density cells being more CD34 positive than the high density group. Investigations with the functional efficacy of such compartments revealed significant improvement of cytotoxic efficacy and phagocytic burst at the high density compartment (HDC) level. The high density compartment was found to be more responsive towards the BRMs compared to the cells of the low density compartment (LDC). It was suggested that use of BRMs in vivo can stimulate a potent functional progenitor compartmentalization in normal as well as leukaemic mice. These observations are expected to help a logistic approach towards combined BRM therapy at the clinical level.

View Article
June 2001
10 Reads

The stimulation by Dendritic cells of Host versus graft reactivity in vivo

Immunology and Cell Biology (1993) 71, 527–533; doi:10.1038/icb.1993.58

Immunology and Cell Biology

Dendritic cells (DC) isolated from peripheral intestinal lymph of inbred Wistar rats were injected into the hind footpads of Hooded CBH/Cbi rats. Administration of 104 and 5 times 105 allogeneic DC produced approximately six-fold increase in popliteal node weight. This is only marginally greater than that caused by similar doses of syngeneic DC and about 30% greater than that caused by allogeneic mononuclear cells. The data indicated that allogeneic DC were not effective stimulators of host-versus-graft reactions in this assay.

View Article
March 1993
9 Reads

Immunological profile of Arsenic toxicity: A hint towards Arsenic-induced Carcinogenesis.

Asian Paci J Can Prev, (2010) 11: 479-490. (Impact Factor 2.39)

Arsenic (a Group I carcinogen in humans) contamination and poisoning of human populations in different parts of Southeast and Eastern Asia, including West Bengal and Bangladesh, has become a major environmental concern. Arsenic intoxication affects diverse human organs including the lungs, liver, skin, bladder and kidney. This metalloid acts as a promoter of carcinogenesis, exerting toxic effects on the immune system. The present study was aimed at investigating arsenic-induced carcinogenesis and effects on the immune system in an animal model. Tumors were induced using ethylnitrosourea (ENU) and arsenic was used as a promoter. To investigate specific effects on the immune system, cytokine (TNF-α, IFNγ, IL4, IL6, IL10, IL12) production of lymphocytes was evaluated by FACS. The damaging consequences of treatment were assessed by evaluating the specific programmed cell death cascade in lymphocytes, assessed by FACS readings. The results revealed that under arsenic influence, and more so with arsenic+ENU, marked neoplastic changes were noted, which were corroborated with histological changes, cytokine modulation and apoptosis hinted at marked neoplastic changes.

View Article
November 0001
1 Read

T11TS immunotherapy repairs PI3K-AKT signalling in T-cells: clues towards enhanced T-cell survival in rat glioma model

J Cell Physiol.(2018) 233:759–770 (Impact Factor 4.522)

Malignant glioma is the most fatal of astrocytic lineage tumors despite therapeutic advances. Onset

and progression of gliomas is accompanied by severe debilitation of T-cell defense and T-cell

survival. One of the chief contributors to T-cell survival downstream of activation is the PI3K-AKT

pathway. Our prior studies showed that the novel immunotherapeutic molecule T11-target structure

(T11TS) blocks T-cell apoptosis in glioma. We also showed activation of immunological synapse

components and calcineurin-NFAT pathway following T11TS immunotherapy of glioma-bearing rats.

This lead to investigations whether such T-cell activation upon T11TS therapy translates into

activation of downstream PI3K/AKT signals which may be related to observed blockade of T-cell

apoptosis. For the purpose, we assessed by flowcytometry and immunoblotting, expressions of PI3K,

PDK1, AKT, p-AKT, and PTEN in splenic T-cells of normal, experimentally-induced glioma-bearing

rats and glioma-bearing rats receiving first, second and third doses of T11TS. We also determined

comparative nuclear translocation of NF-κB across groups. We found significant increases in T-cell

expressions of PDK1, PI3K and p-AKT in T11TS-treated animal groups compared to sharp

downregulations in glioma. AKT levels remained unchanged across groups. PTEN levels declined

sharply after T11TS immunotherapy. T11TS also caused enhanced NF-κB translocation to the T-cell

nucleus compared to glioma group. Results showed heightened activation of the PI3K-AKT pathway

in glioma-bearing rats following T11TS immunotherapy. These results illustrate the novel role of

T11TS immunotherapy in ameliorating the PI3K pathway in T-cells in glioma-bearing animals to

enhance T-cell survival, according greater defense against glioma. The study thus has far-reaching

clinical outcomes.

View Article
November 0001
3 Reads

Microglial action in glioma: A boon turns bane

Immunol Lett.(2010)131: 3–9. (Impact Factor 2.552)

Microglia has the potential to shape the neuroimmune defense with vast array of functional attributes.

The cells prime infiltrated lymphocytes to retain their effector functions, play crucial role in controlling

microenvironmental milieu and significantly participate in glioma. Reports demonstrate microglial

accumulation in glioma and predict their assistance in glioma growth and spreading. Clarification of the

‘double-edged’ appearance of microglia is necessary to unfold its role in glioma biology. In this article

the interpretation of microglial activities has been attempted to reveal their actual function in glioma.

Contrary to the trendy acceptance of its glioma promoting infamy accumulated evidences make an effort

to view the state of affairs in favor of the cell. Critical scrutiny indicates that microglial immune assaults

are intended to demolish the neoplastic cells in brain. But the weaponry of microglia has been tactically

utilized by glioma in their favor as the survival strategy. Hence the defender appears as enemy in

advanced glioma.

View Article
November -0001
2 Reads